Cargando…

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer

SIMPLE SUMMARY: Disease progression while receiving treatment is a major problem in breast cancer. Mutations in the oestrogen receptor-α often lead to loss of drug activity, resulting in an inability of anti-oestrogens to stop cancer growth. There is an urgent need to establish which therapies can e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mayayo-Peralta, Isabel, Faggion, Beatrice, Hoekman, Liesbeth, Morris, Ben, Lieftink, Cor, Goldsbrough, Isabella, Buluwela, Lakjaya, Siefert, Joseph C., Post, Harm, Altelaar, Maarten, Beijersbergen, Roderick, Ali, Simak, Zwart, Wilbert, Prekovic, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699146/ https://www.ncbi.nlm.nih.gov/pubmed/34944934 http://dx.doi.org/10.3390/cancers13246314

Ejemplares similares

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription
por: Mayayo-Peralta, Isabel, et al.
Publicado: (2023)

It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivities
por: Lieftink, Cor, et al.
Publicado: (2021)

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer
por: Prekovic, Stefan, et al.
Publicado: (2021)

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
por: Palit, Sander AL, et al.
Publicado: (2019)

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer
por: Palit, Sander A. L., et al.
Publicado: (2021)

CDK7 inhibitors as anticancer drugs
por: Sava, Georgina P., et al.
Publicado: (2020)

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer
por: Iskit, Sedef, et al.
Publicado: (2016)

Ribosome impairment regulates intestinal stem cell identity via ZAKɑ activation
por: Silva, Joana, et al.
Publicado: (2022)

Mammalian life depends on two distinct pathways of DNA damage tolerance
por: Buoninfante, Olimpia Alessandra, et al.
Publicado: (2023)

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
por: Martin, Lesley-Ann, et al.
Publicado: (2017)

Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen
por: Schepers, Arnout, et al.
Publicado: (2021)

Androgen and glucocorticoid receptor direct distinct transcriptional programs by receptor-specific and shared DNA binding sites
por: Kulik, Marina, et al.
Publicado: (2021)

Identification of signalling cascades involved in red blood cell shrinkage and vesiculation
por: Kostova, Elena B., et al.
Publicado: (2015)

The RECQL helicase prevents replication fork collapse during replication stress
por: Benedict, Bente, et al.
Publicado: (2020)

High‐throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells
por: Tuijnenburg, Paul, et al.
Publicado: (2019)

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
por: Diplas, Bill H., et al.
Publicado: (2018)

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
por: Šuštić, Tonći, et al.
Publicado: (2018)

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
por: Šuštić, Tonći, et al.
Publicado: (2021)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer
por: Harrod, Alison, et al.
Publicado: (2022)

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
por: Serresi, Michela, et al.
Publicado: (2018)

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
por: Pandey, Gaurav Kumar, et al.
Publicado: (2023)

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
por: Linder, Simon, et al.
Publicado: (2018)

ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942
por: Sava, Georgina P., et al.
Publicado: (2019)

Ribociclib-induced Vitiligo: a Case Report
por: Silvestre Torner, Nicolás, et al.
Publicado: (2022)

The Tumor Coagulome as a Transcriptional Target and a Potential Effector of Glucocorticoids in Human Cancers
por: Racine, Floriane, et al.
Publicado: (2023)

A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer
por: Jin, Haojie, et al.
Publicado: (2020)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

The ESR Patient Advisory Group (ESR-PAG)
Publicado: (2015)

Case Report of Probable DRESS Syndrome Associated with Ribociclib
por: Carneiro, Florian, et al.
Publicado: (2023)

ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases
por: Lopez-Garcia, Jorge, et al.
Publicado: (2006)

ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation
por: Li, Zheqi, et al.
Publicado: (2022)

Multistep mechanism of G-quadruplex resolution during DNA replication
por: Sato, Koichi, et al.
Publicado: (2021)

Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK directed activation of NF-κB
por: Periyasamy, Manikandan, et al.
Publicado: (2021)

Ribociclib: a valuable addition to treatment options in breast cancer?
por: Bartsch, Rupert
Publicado: (2017)

Ribociclib and palbociclib-induced erythema multiforme: a case report
por: Vrana, Eleni, et al.
Publicado: (2022)

Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
por: Coffman, Lan G., et al.
Publicado: (2022)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells
por: Li, Bohui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j0n78kvj2lmnn43ddht6o8rbtl